Dynavax Technologies reported $128.24M in Operating Expenses for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Operating Expenses Change
Abbvie ABBV:US $ 11288M 2467M
Adma Biologics ADMA:US $ 16.94M 33.64M
Agenus AGEN:US $ 65.49M 4.09M
Amgen AMGN:US $ 4.42B 680M
AstraZeneca AZN:LN 10.23B 280M
Astrazeneca AZN:US 10.23B 280M
Biogen BIIB:US $ 2648.2M 727.1M
Biomarin Pharmaceutical BMRN:US $ 494.65M 112.61M
Bristol Myers Squibb BMY:US $ 9.3B 202M
Chimerix CMRX:US 23.89M 899K
Dynavax Technologies DVAX:US $ 128.24M 45.01M
Gilead Sciences GILD:US $ 4231M 2162M
Glaxosmithkline GSK:US 5.85B 1.13B
Idera Pharmaceuticals IDRA:US $ 5.36M 1.18M
Merk MRK:US $ 9666M 666M
Minerva Neurosciences NERV:US $ 6.97M 1.02M
Nektar Therapeutics NKTR:US $ 174.42M 33.04M
Neurocrine Biosciences NBIX:US $ 393.5M 86M
Novartis NOVN:VX 10.86B 895M
Pfizer PFE:US $ 15640M 148M
Regeneron Pharmaceuticals REGN:US $ 1747.3M 40.7M
Sarepta Therapeutics SRPT:US $ 444.62M 146.91M
Tg Therapeutics TGTX:US $ 39.53M 29.35M
Vertex Pharmaceuticals VRTX:US $ 1089.9M 33.3M